Objective     To evaluate the early clinical outcomes of the Renatus® balloon-expandable valve in the treatment of severe aortic stenosis. Methods    From November 2021 to April 2022, a total of 38 patients who received Renatus® balloon-expandable valve for severe aortic stenosis in Guangdong Provincial People&#39;s Hospital were included. There were 22 males and 16 females, with an average age of 73.7±5.3 years. Mean aortic gradient and peak aortic jet velocity at baseline, post-procedure, and follow-up were compared. Clinical outcomes including all-cause mortality, perivalvular leakage, serious adverse cardiovascular events and the occurrence of permanent pacemaker implantation were assessed. Results    All patients completed the procedure successfully without conversion to thoracotomy or perioperative death. The post-implant mean aortic pressure gradient was decreased from 41.5 (27.8, 58.8) mm Hg to 6.0 (3.0, 8.0) mm Hg, and the peak aortic jet velocity was also decreased from 4.1±0.9 m/s to 1.7±0.4 m/s (P<0.001). Pacemakers were required in 2 (5.3%) patients. The median follow-up time was 27.5 (23.0, 87.5) d, with a follow-up rate of 100.0%. The mean aortic gradient was 8.0 (7.0, 10.8) mm Hg and peak aortic jet velocity was 2.0±0.3 m/s, showing significant improvement compared with those in the preoperative period (P<0.001). No severe aortic regurgitation or paravalvular leak was observed. There was no serious cardiovascular adverse event or reoperative event during the study period. Conclusion    Transcatheter aortic valve replacement with the domestic Renatus® balloon-expandable valve system is a safe and effective procedure for selected patients with severe aortic stenosis who are at high risk or not candidates for surgical aortic valve replacement.

[摘 要] 目的：探讨miR-620对乳腺癌MCF-7细胞放射敏感性的影响及其机制。方法：收集2017年3月至2018年3月在海南省儋州市人民医院手术切除的21例乳腺癌患者的癌及癌旁组织标本，以及乳腺癌细胞MCF-7、BCaP-37和乳腺上皮细胞HBL-100，采用qPCR法检测癌组织和细胞中miR-620和生长抑制因子4（ING4）mRNA的表达。利用脂质体转染技术，分别将miR-620抑制剂（anti-miR-620）和抑制剂阴性对照（anti-miR-NC）、anti-miR-620和ING4小干扰RNA（si-ING4）、anti-miR-620和小干扰RNA阴性对照序列（si-NC）转染至MCF-7细胞，经放射处理后（依次记为IR+anti-miR-620组、IR+anti-miR-NC组、IR+anti-miR-620+si-ING4组、IR+anti-miR-620+si-NC组），利用克隆形成实验、MTT法和FCM分别检测细胞放射敏感性、细胞增殖活力、细胞周期分布和凋亡率。双荧光素酶报告基因实验和WB法验证miR-620和ING4的靶向关系。结果：与癌旁组织和HBL-100细胞比较，乳腺癌组织和细胞中miR-620表达均显著升高（均P<0.01）、ING4 mRNA表达均显著降低（均P<0.01）。与IR+anti-miR-NC组比较，IR+anti-miR-620组MCF-7细胞增殖活力、S期细胞比例均显著降低（均P<0.01），细胞凋亡率、G0-G1期细胞比例、放射敏感性均显著升高（均P<0.01）。与IR+anti-miR-620+si-NC组比较，IR+anti-miR-620+si-ING4组MCF-7细胞增殖活力、S期细胞比例均显著升高（均P<0.01），细胞凋亡率、G0-G1期细胞比例和放射敏感性均显著降低（均P<0.01）。双荧光素酶报告基因实验证明ING4是miR-620的靶基因，miR-620靶向负性调控ING4表达。结论：敲减miR-620可能通过上调ING4表达抑制乳腺癌MCF-7细胞增殖，并促进细胞凋亡和放射敏感性。